We recently identified CD46 as a novel therapeutic target in prostate cancer (PCa). In the present study, we developed a novel CD46-targeted positron emission tomography (PET) radiopharmaceutical, [89Zr]DFO-YS5, and evaluated its performance for immunoPET imaging in murine PCa models.